Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans

Reference

• BACKMAN, J. T., OLKKOLA, K. T., ARANKO, K., HIMBERG, J. J. and NEUVONEN, P. J., 1994, Dose of midazolam should be reduced during diltiazem and verapamil treatments. British Journal of Clinical Pharmacology, 37, 221–225.
   PubMed Web of Science ®Google Scholar
• BAXTER, J. G., BRASS, C., SCHENTAG, J. J. and SLAUGHTER, R. L., 1986, Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to human and dogs. Journal of Pharmaceutical Sciences, 75, 443–447.
   PubMed Web of Science ®Google Scholar
• BJORNSSON, T. R., CALLAGHAN, J. T., EINOLF, H. J., FISCHER, V., GAN, L., GRIMM, S., KAO, J., KING, S. P., MIWA, G., NI, L., KUMAR, G., McLEon, J., OBACH, R. S., ROBERTS, S., ROE, A., SHAH, A., SNIKERIS, F., SULLIVAN, J. T., TWEEDIE, D., VEGA, J. M., WALSH, J. and WRIGHTON, S. A., 2003, The conduct of in vitro and in vivo drug—drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metabolism and Disposition, 31, 815–832.
   PubMed Web of Science ®Google Scholar
• GAILLARD, Y., GAY-MONTCHAMP, J. P. and OLLAGNIER, M., 1993, Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection after solid-phase extraction. Journal of Chromatography, 622, 197–208.
   Google Scholar
• GASCON, M. P. and DAYER, P., 1991, In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. European Journal of Clinical Pharmacology, 41, 573–578.
   PubMed Web of Science ®Google Scholar
• GHOSAL, A., SATO, H., THOMAS, P. E., BUSH, E. and MOORE, D., 1996, Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940–947.
   PubMed Web of Science ®Google Scholar
• GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643–1653.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1999 Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1–17.
   PubMed Web of Science ®Google Scholar
• HIGASHIKAWA, F., MURAKAMI, T., KANEDA, T., KATO, A. and TAKANO, M., 1999, Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. Journal of Pharmacy and Pharmacology, 51, 67–72.
   PubMed Web of Science ®Google Scholar
• IGARASHI, T., SAKUMA, T., IsoGAI, M., NAGATA, R. and KAMATAKI, T., 1997, Marmoset liver cytochrome P450s: study for expression and molecular cloning of their cDNAs. Archives of Biochemistry and Biophysics, 339, 85–91.
   PubMed Web of Science ®Google Scholar
• ITo, K., IWATSUBO, T., KANAMITSU, S., UEDA, K., SUZUKI, H. and SUGIYAMA, Y., 1998, Prediction of pharmacokinetic alterations caused by drug—drug interactions: metabolic interaction in the liver. Pharmacological Reviews, 50, 387–411.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., 00IE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T. GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–171.
   Google Scholar
• KREMERS, P., 2002, Can drug—drug interactions be predicted from in vitro studies? Scientific World Journal, 2, 751–766.
   Google Scholar
• KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89–96.
   PubMed Web of Science ®Google Scholar
• LADDISON, K. J., SPEIRS, A., MANKOWSKI, D. C., TWEEDIE, D. and LAWTON, M. P., 1995, Cloning, sequencing, and expression of the cynomolgus monkey liver cytochrome P450 that is orthologous to human CYP2D6. ISSX Proceedings, 8, 367.
   Google Scholar
• LESAR, T. S., BRICELAND, L. and STEIN, D. S., 1997, Factors related to errors in medication prescribing. Journal of the American Medical Association, 277, 312–317.
   PubMed Web of Science ®Google Scholar
• LILLSUNDE, P. and SEPPALA, T., 1990, Simultaneous screening and quantitative analysis of benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection. Journal of Chromatography, 533, 97–110.
   PubMed Web of Science ®Google Scholar
• MATSUBARA, T., OTSUBO, S. and YOSHIHARA, E., 1983, Liver microsomal cytochrome P-450-dependent 0-dealkylation reaction in various animals. Japanese Journal of Pharmacology, 33, 1065–1075.
   PubMedGoogle Scholar
• RING, B. J., PARLI, C. J., GEORGE, M. C. and WRIGHTON, S. A., 1994, In vitro metabolism of zatosetron. Interspecies comparison and role of CYP3A. Drug Metabolism and Disposition, 22, 352–357.
   PubMed Web of Science ®Google Scholar
• SHARER, J. E., SHIPLEY, L. A., VANDENBRANDEN, M. R., BINKLEY, S. N. and WRIGHTON, S. A., 1995, Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231–1241.
   PubMed Web of Science ®Google Scholar
• SPATZENEGGER, M. and JAEGER, W., 1995, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews, 27, 397–417.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., HARTWELL, P. S., RAISYS, V. A., MARSH, C. L., McVicAR, J. P., BARR, D. M., PERKINS, J. D. and CARITHERS, R. L., 1994a, Use of midazolam as a human cytochrome P450 3A probe: I. In vitro—in vivo correla-tions in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549–556.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., BACCHI, C. E., MARSH, C. L., McVicAR, J. P., BARR, D. M., PERKINS, J. D. and CARITHERS, R. L., 1994b, Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271, 557–566.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E. and WILKINSON, G. R., 1998, In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology, 38, 389–430.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., WRIGHT, C. E., HARMATZ, J. S. and SHADER, R. I., 1998, In vitro approaches to predicting drug interactions in vivo. Biochemical Pharmacology, 55, 113–122.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed 1' -hydroxyl midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceutical Research, 11, 921–924.
   PubMed Web of Science ®Google Scholar
• Wu, D., OTTON, V., MORROW, P., INABA, T., KALOW, W. and SELLERS, E. M., 1993, Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. Journal of Pharmacology and Experimental Therapeutics, 266, 715–719.
   PubMed Web of Science ®Google Scholar
• YAKATAN, G. J., POYNOR, W. J., HARRIS, R. G., MARTIN, A., LEONARD, R. G., BRIGGS, A. H. and DoLuisio, J. T., 1979, Single-dose fasting bioequivalence assessment of erythromycin stearate tablets in man. Journal of Pharmacokinetics and Biopharmaceutics, 7, 355–368.
   PubMedGoogle Scholar
• YASUMORI, T., CHEN, L., NAGATA, K., YAMAZOE, Y. and KATO, R., 1992, Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). Journal of Pharmacology and Experimental Therapeutics, 264, 89–94.
   Web of Science ®Google Scholar